Highlighting gene expression differences in the Alzheimer's brain
A greater understanding of Alzheimer's disease pathogenesis is essential for the development of more effective treatments. To gain these insights, researchers aim for a clear picture of the gene expression during initiation and progression of disease. These studies have been hampered in the past by conflicting expression results and suboptimal use of precious samples such as brain tissue. The advent of NGS RNAseq technologies enables researchers to get the maximum amount of unequivocal expression data from their samples.
QIAGEN provides sample and assay technologies for RNAseq that ensure reliable, reproducible results from sample to insight. Consistently high-quality RNA prep, unbiased whole transcriptome amplification, effective rRNA depletion, rapid library construction, and sequencing on any platform are assured in the workflow. To dicover the diversity in the data, QIAGEN's user-friendly bioinformatics solutions highlight differential and alternative gene expression and places it in the meaningful context of relevant biological pathways and processes.